linjc16/ctgov huggingface dataset:
Antagonist Protocol in IVF

Study Overview
=================
Brief Summary
-----------------
The antagonist protocol in a novel method of stimulation in the in vitro fertilization (IVF) patients. It has been tried in poor responders, polycystic ovary (PCO) patients and normal females undergoing IVF. Can it be used with the same efficacy in all patients?

Official Title
-----------------
Can Antagonist Protocol be the Protocol of Choice in in Vitro Fertilization Patients?

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: Gonadotropins releasing hormone antagonist


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age: 20- 44 years Poor responder females according to Bologna criteria Polycystic ovarian disease females according to Rotterdam criteria Females with infertility causes other than poor responders, or PCO; male factor or tubal block Exclusion Criteria: refusal to get enrolled in the study cases of infertility due to severe male factor

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Normal<br>Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC. | Drug: Gonadotropins releasing hormone antagonist<br> <br> * Other names: Cetrotide, Serono, Geneva, Switzerland;|
| Active Comparator: Poor responders<br>Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC | Drug: Gonadotropins releasing hormone antagonist<br> <br> * Other names: Cetrotide, Serono, Geneva, Switzerland;|
| Active Comparator: Polycystic ovarian disease<br>Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC | Drug: Gonadotropins releasing hormone antagonist<br> <br> * Other names: Cetrotide, Serono, Geneva, Switzerland;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of oocytes collected and fertilized |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infertility
Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The score on the Edmonton frail scale will be recorded in 250 consecutive patient aged of 75 years or more and undergoing elective cardiac surgery. In those patients the investigators will also record the ITU length of stay, the hospital length of stay, the incidence of complications, the ability to be discharged home and to live independently at postoperative day 30. The ability of the Edmonton score to predict complication, prolonged hospital and ITU length of stay as well as loss of autonomy at discharge and day 30 will be assessed.

Official Title
-----------------
Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery

Conditions
-----------------
Elective Cardiac Surgery

Intervention / Treatment
-----------------
* Other: Non


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 75 yo and older Elective cardiac surgery Exclusion Criteria: Refuse or inability to give consent Emergency surgery

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiac surgery<br> | Other: Non<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30-day mortality |  | 30 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Loss of autonomy at discharge (Edmonton score) |  | 30 Days | 
| Loss of autonomy at day 30 (Edmonton score) |  | 30 days | 
| Incidence of predefined complications |  | 30 Days | 
| Length of hospital stay |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aged of 75 years or more
Fluoroscopic &Ultrasonographic Guidance of Superior Hypogastric Plexus Neurolysis in Intractable Pelvic Pain

Study Overview
=================
Brief Summary
-----------------
fluoroscopic group & includes 30 patients where SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.the double modality group & includes 30 patients where SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position.

Official Title
-----------------
The Role of Double Modality  Fluoroscopic &Ultrasonographic  Guidance of Superior Hypogastric Plexus Neurolysis in Treating Intractable Pelvic Cancer Pain: a Comparative Study.

Conditions
-----------------
Intractable Pelvic Cancer Pain

Intervention / Treatment
-----------------
* Procedure: fluroscopic guided block
* Procedure: double modality (ultrasound and fluroscopic) guided block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years. Intractable pelvic cancer pain (VAS > 40 mm) Pain is refractory to pharmacotherapy (both opioids and adjuvant therapy) or opioids' side effects are not tolerated. Exclusion criteria Local or systemic sepsis. Uncorrectable coagulopathy. Neuropsychiatric illness. History of drug abuse. Pregnant or lactating patients. Distorted local anatomy. Patients who are known to be allergic to the used medications. Cardiovascular or respiratory instability.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: fluroscopic guided block<br> | Procedure: fluroscopic guided block<br>* SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.<br>|
| Experimental: double modality guided block<br> | Procedure: double modality (ultrasound and fluroscopic) guided block<br>* SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position. Then C-arm pictures will be checked (both P-A & dead lateral)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain relief will be assessed by VAS | pain relief will be assessed by VAS (visual Analogue score) which is 100 mscale with left (0) end means no pain & right (10) end means the worst possible pain | 12 weeks |
Endothelial Dysfunction Induced by Postprandial Lipemia

Study Overview
=================
Brief Summary
-----------------
Postprandial lipemia and exercise oppose each other in terms of cardiovascular risk, however the mechanism of their interaction is not well understood. Therefore we want to study vascular function, as assessed by brachial artery (BA) flow mediated dilation (FMD), in healthy men before and after a high fat meal (HFM) preceded (16-18 hrs) by rest, a single bout of continuous moderate intensity exercise (CME), and high intensity interval exercise (HIIE).

Official Title
-----------------
Endothelial Dysfunction Induced by Postprandial Lipemia: Complete Protection Afforded by High Intensity Aerobic Interval Exercise

Conditions
-----------------
Healthy Subjects

Intervention / Treatment
-----------------
* Other: exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male, 20-40years, BMI between 25 and 30, resident in Trondheim. Exclusion Criteria: unstable angina, CHD, heart failure,

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br>Control | |
| No Intervention: 2<br>moderate exercise training group | |
| Experimental: 3<br>high intensity exercise group | Other: exercise training<br>* moderate intensity exercise group, and high intensity exercise group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Flow mediated dilatation |  | baseline, post exercise, 30min, 2hour, 4hour post exercise | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood lipid profile |  | same as flow mediated dilatation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
flow mediated dilatation, maximal oxygen uptake, blood lipid
MRI Study of Ballooning and Ligamentisation Short Transplants ACL Hamstring According to Technical DT4

Study Overview
=================
Brief Summary
-----------------
MRI study of ballooning and ligamentisation short transplants of anterior cruciate ligament (ACL) according to DT4 technique in 60 patients with more than one year of follow up.

Detailed Description
-----------------
Monocentric study in the CHRU Lille in which the first goal is to estimate the frequency of tunnel's ballooning in a surgical anterior cruciate ligament reconstruction using short transplants of hamstrings. the secondary goals Secondary goals of this study are the estimation of ligamentisation if ballooning or not, the comparison of sagittal laximetry between ballooned group and not balloonedone, the clinical results in IKDC score (International Knee Documentation Committee subjective fee form) and KOOS (Knee injury Osteoarthritis Outcome Score) between the ballooned group and the not balloonedone.

Official Title
-----------------
MRI Study of Ballooning and Ligamentisation Short Transplants ACL Hamstring According to Technical DT4

Conditions
-----------------
Deficiency of Anterior Cruciate Ligament, Displacement of Bone Allograft

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults patients of both sexes with an hamstring ACL ligamentoplasty done in our institution with a follow up of 1 year isolated ACL ligamentoplasty insured patients with a signed informed consent Exclusion Criteria: follow up inferior of 1 year absolute contraindication to knee MRI gadolinium allergy severe renal failure non isolated ACL ligamentoplasty patient under guardianship, minor pregnant woman or nursing mother

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ACL reconstruction ballooning<br>ACL reconstruction with short hamstring tendon autograft arm ballooning arm no ballooning | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency of balloonisation | oversize of the diameters of femoral and /or tibial tunnels more than 50% of their surgical diameter | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency of ligamentisation | fixation on MRI of gadolinium in ligament graft | 1 year | 
| laximetry done with genurob* | measure of the residual anterior laxity on an electronic device | 1 year | 
| Knee Injury and Osteoarthritis Outcome Score | clinical measures | 1 year | 
| International Knee Documentation Commitee (IKDC) Score | clinical measures | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI, knee, short hamstring autograft, ligament
Observation Study of the Medication Switch at Patients Treated With Sitaxentan to a Regime Without Sitaxentan

Study Overview
=================
Brief Summary
-----------------
Due to the withdrawal of Thelin (Sitaxentan) in December 2010 all patients with pulmonary hypertension treated with Sitaxentan need to be switched to an alternative therapy. This study will observe in which way the change of medication - in the clinical routine, without exception in charge of the treating physician - affects clinical and laboratory parameters and patient's quality of life.

Official Title
-----------------
Clinical Devolution of a Medication Change at Patients With Mono- or Combination Therapy With Sitaxentan to a Regime Without Sitaxentan.

Conditions
-----------------
Hypertension, Pulmonary

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pulmonary hypertension Treatment with Sitaxentan Exclusion Criteria: Inability or unwillingness to give written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

Study Overview
=================
Brief Summary
-----------------
Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC participants still receiving care but at high risk for disengagement and to intervene to prevent/delay disengagement.

Detailed Description
-----------------
In Phase 1 of the project, we will confirm a model predicting factors associated with later disengagement from CSC treatment. In Phase 2, we will compare disengagement among high-risk individuals with a CSC Step-down intervention to that with standard CSC care. The Step-down intervention will use web-based telemedicine and a smartphone app, to decrease disengagement likelihood. High-risk participants identified by predictors found in Phase 1 will be offered the intervention.

Official Title
-----------------
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

Conditions
-----------------
First Episode Psychosis

Intervention / Treatment
-----------------
* Other: CSC Step-down intervention
* Other: Usual Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Enrolled into a CSC program Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Assigned to either treatment as usual or to the disengagement treatment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: CSC Step-down intervention<br>Web-based telemedicine and a smartphone app, to decrease disengagement likelihood | Other: CSC Step-down intervention<br>* Web-based telemedicine and a smartphone app, to decrease disengagement likelihood<br>|
| Other: Usual Care<br>Usual care provided by CSC center | Other: Usual Care<br>* Usual Care provided by CSC center<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disengagement rate | Rate of disengagement from CSC program | Minimum of 6 months |
Use of Atropine in Tredmill Stress Testing

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the Safety and feasibility of atropine added during treadmill stress testing in patients with chronotropic incompetence or poor exercise capacity. Our hypothesis is that we can increase heart rate by using atropin in these patients, so we will achieve more conclusive results.

Official Title
-----------------
Safety and Feasibility of Atropine Added During Treadmill Stress Testing in Patients With Chronotropic Incompetence or Poor Exercise Capacity.

Conditions
-----------------
Chest Pain

Intervention / Treatment
-----------------
* Drug: Atropine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with chest pain without evidence of ischemia eligible for exercise test. Age> 18 years old Exclusion Criteria: Absolute: Patients with LBBB Unstable Angina Recent Myocardial Infarction Un controlled Arrythmia Congestive heart faliure Severe symptomatic valvular heart disease Acute Pulmonary Embolism Acute perimyocarditis Acute aortic dissection Relative: Lt main stenosis Severe hypertention (Systolic> 200 mmHg; Diastolic > 100 mmHg) Cardiomyopathy Obstructiove abnormalities Psychiatric disorders High degree AV Block

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>Pateints who achieve target haert rate or conclusive test will not be given Atropine | Drug: Atropine<br>* I.V Atropine 0.5mg up to 2 mg<br>|
| Active Comparator: 2<br>Patients who won't achieve tarhet heart rate or conclusive results will be given Atropine | Drug: Atropine<br>* I.V Atropine 0.5mg up to 2 mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1- To characterize patients who can't achieve target heart rate at treadmill exercise test.2- To evaluate atropine added during treadmill stress testing in order to increase heart rate and achieave conclusive test. |  | 1 yaer | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chest Pain Low work Capacity Rate Incompetence
Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice

Study Overview
=================
Brief Summary
-----------------
A Multi-center, Randomized, Vehicle Controlled, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the treatment of Head Lice.

Official Title
-----------------
A Multi-Center, Randomized, Vehicle Controlled, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice.

Conditions
-----------------
Head Lice

Intervention / Treatment
-----------------
* Drug: Summers 5% L.A.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females 6 months of age or older. Have an active infestation with Pediculus capitis, the human head louse, with at least three live lice at baseline. Agree not to use any other pediculicides or medicated hair-grooming products during the duration of the study. Be healthy, non-febrile, and not suffering from an infection likely to require antibiotic therapy during the study period. Subject or guardian is able to understand the new HIPAA regulations and sign the HIPAA form. Subject or guardian has read, understood, and signed appropriate informed consent in English. If English is not the primary language, the information about the study must be explained in their language and a copy of the informed consent must be in that language. Subject is willing to participate in the study, and abide by the protocol requirements. Exclusion Criteria: Participation in any clinical study within the past 30 days. Known hypersensitivity to any ingredient in the product formulation.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Summers 5% L.A.|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment success is defined as the absence of live lice. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The cumulative proportions of subjects determined to be treatment failures at the Second Evaluation Visit. |  |  |